The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Targeting leukocyte MMPs and transmigration
Open accessAbstract
Multiple sclerosis is characterized by the infiltration of leukocytes into the CNS. As matrix metalloproteinases (MMPs) facilitate the passage of leukocytes across matrix barriers, we tested the hypothesis that targeting MMPs could attenuate neuro-inflammation. We report that minocycline, a widely used generic drug with a good safety record, inhibited MMP activity, reduced production of MMP-9 and decreased the transmigration of T lymphocytes across a fibronectin matrix barrier. In addition, minocycline was efficacious against both mild and severe experimental autoimmune encephalomyelitis (EAE) in mice, an animal model of multiple sclerosis. When severe EAE was produced, minocycline pre-treatment delayed the course of the disease: when maximal disease activity occurred in vehicle-treated EAE mice, minocycline animals were relatively normal and had minimal signs of inflammation and demyelination in the CNS. When tested in mice afflicted with mild EAE, minocycline attenuated the clinical severity of disease throughout the course of treatment. These results indicate that minocycline may constitute a safe and inexpensive therapy for multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Metalloproteinases in biology and pathology of the nervous system
Yong, V. W., Power, C., Forsyth, P., & Edwards, D. R. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081571 · Cited by 1,060
Self-citationChen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,051
Yrjänheikki, J., Tikka, T., Keinänen, R., Goldsteins, G., Chan, P. H., & Koistinaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,038
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
Liu, J., Marino, M. W., Wong, G., Grail, D., Dunn, A., Bettadapura, J., Slavin, A. J., Old, L., & Bernard, C. C. A. (1998) · Nature Medicine · doi:10.1038/nm0198-078 · Cited by 550
Self-citationChen, D., Endres, R. L., Erickson, C. A., Weis, K. F., McGregor, M. W., Kawaoka, Y., & Payne, L. G. (2000) · Nature Medicine · doi:10.1038/80538 · Cited by 547
Tikka, T. M., & Koistinaho, J. E. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7527 · Cited by 530
Cited by
Inflammation is detrimental for neurogenesis in adult brain
Ekdahl, C. T., Claasen, J.-H., Bonde, S., Kokaia, Z., & Lindvall, O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2234031100 · Cited by 1,559
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Hu, J., Van den Steen, P. E., Sang, Q.-X. A., & Opdenakker, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2308 · Cited by 795
Tetracyclines: Nonantibiotic properties and their clinical implications
Sapadin, A. N., & Fleischmajer, R. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.004 · Cited by 768
Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Ledeboer, A., Sloane, E. M., Milligan, E. D., Frank, M. G., Mahony, J. H., Maier, S. F., & Watkins, L. R. (2005) · Pain · doi:10.1016/j.pain.2005.02.009 · Cited by 677
Metalloproteinases: Mediators of Pathology and Regeneration in the CNS
Yong, V. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1807 · Cited by 582
Self-citationStroke and the immune system: from pathophysiology to new therapeutic strategies
Macrez, R., Ali, C., Toutirais, O., Le Mauff, B., Defer, G., Dirnagl, U., & Vivien, D. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70066-7 · Cited by 560
The Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
Stirling, D. P., Khodarahmi, K., Liu, J., McPhail, L. T., McBride, C. B., Steeves, J. D., Ramer, M. S., & Tetzlaff, W. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5275-03.2004 · Cited by 507
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Self-citationMinocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Minocycline treatment in acute stroke: An open-label, evaluator-blinded study
Lampl, Y., Boaz, M., Gilad, R., Lorberboym, M., Dabby, R., Rapoport, A., Anca-Hershkowitz, M., & Sadeh, M. (2007) · Neurology · doi:10.1212/01.wnl.0000277487.04281.db · Cited by 440
Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice
Wells, J. E. A. (2003) · Brain · doi:10.1093/brain/awg178 · Cited by 422
Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases
Power, C., Henry, S., Del Bigio, M. R., Larsen, P. H., Corbett, D., Imai, Y., Yong, V. W., & Peeling, J. (2003) · Annals of Neurology · doi:10.1002/ana.10553 · Cited by 363
Self-citationBar-Or, A. (2003) · Brain · doi:10.1093/brain/awg285 · Cited by 360
Zipp, F., & Aktas, O. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.006 · Cited by 348
Tsutsui, S., Schnermann, J., Noorbakhsh, F., Henry, S., Yong, V. W., Winston, B. W., Warren, K., & Power, C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4271-03.2004 · Cited by 323
Self-citationBosco, A., Inman, D. M., Steele, M. R., Wu, G., Soto, I., Marsh-Armstrong, N., Hubbard, W. C., Calkins, D. J., Horner, P. J., & Vetter, M. L. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1337 · Cited by 323
Oxidative and nitrative stress in neurodegeneration
Cobb, C. A., & Cole, M. P. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.020 · Cited by 298
Microglia and neuropathic pain
Inoue, K., & Tsuda, M. (2009) · Glia · doi:10.1002/glia.20871 · Cited by 290
Mika, J., Osikowicz, M., Makuch, W., & Przewlocka, B. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.01.013 · Cited by 290
Potential Role for the Gut Microbiota in Modulating Host Circadian Rhythms and Metabolic Health
Parkar, S. G., Kalsbeek, A., & Cheeseman, J. F. (2019) · Microorganisms · doi:10.3390/microorganisms7020041 · Cited by 285
Minocycline as a Neuroprotective Agent
Stirling, D. P., Koochesfahani, K. M., Steeves, J. D., & Tetzlaff, W. (2005) · The Neuroscientist · doi:10.1177/1073858405275175 · Cited by 279
Synaptic circuit remodelling by matrix metalloproteinases in health and disease
Huntley, G. W. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3320 · Cited by 267
Interleukin‐1β promotes oligodendrocyte death through glutamate excitotoxicity
Takahashi, J. L., Giuliani, F., Power, C., Imai, Y., & Yong, V. W. (2003) · Annals of Neurology · doi:10.1002/ana.10519 · Cited by 256
Self-citationImproving the translational hit of experimental treatments in multiple sclerosis
Vesterinen, H. M., Sena, E. S., ffrench-Constant, C., Williams, A., Chandran, S., & Macleod, M. R. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510379612 · Cited by 182
Pasquini, L. A., Calatayud, C. A., Bertone Uña, A. L., Millet, V., Pasquini, J. M., & Soto, E. F. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9165-0 · Cited by 176
Clinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157
Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis
Lengfeld, J. E., Lutz, S. E., Smith, J. R., Diaconu, C., Scott, C., Kofman, S. B., Choi, C., Walsh, C. M., Raine, C. S., Agalliu, I., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609905114 · Cited by 152
The Potential of Minocycline for Neuroprotection in Human Neurologic Disease
Zemke, D., & Majid, A. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000150867.98887.3e · Cited by 125
“Minocycline and other tetracyclines have been shown to inhibit the activity of MMPs.”
BackgroundInfluentialZabad, R. K., Metz, L. M., Todoruk, T. R., Zhang, Y., Mitchell, J. R., Yeung, M., Patry, D. G., Bell, R. B., & Yong, V. W. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506070319 · Cited by 120
Self-citationKoistinaho, M., Malm, T. M., Kettunen, M. I., Goldsteins, G., Starckx, S., Kauppinen, R. A., Opdenakker, G., & Koistinaho, J. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600040 · Cited by 120
Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice
Stack, E. C., Smith, K. M., Ryu, H., Cormier, K., Chen, M., Hagerty, S. W., Del Signore, S. J., Cudkowicz, M. E., Friedlander, R. M., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.11.002 · Cited by 114
Gerwien, H., Hermann, S., Zhang, X., Korpos, E., Song, J., Kopka, K., Faust, A., Wenning, C., Gross, C. C., Honold, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8020 · Cited by 113
The microglia in healthy and diseased retina
Li, L., Eter, N., & Heiduschka, P. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.04.020 · Cited by 112
Minocycline treatment for HIV-associated cognitive impairment: Results from a randomized trial
Sacktor, N., Miyahara, S., Deng, L., Evans, S., Schifitto, G., Cohen, B. A., Paul, R., Robertson, K., Jarocki, B., Scarsi, K., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f0412 · Cited by 87
Yang, F., Liu, Z., Chen, J., Zhang, S., Quan, Q., Huang, Y., & Jiang, W. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22224 · Cited by 80
Endogenous and synthetic MMP inhibitors in CNS physiopathology.
Baranger, K., Rivera, S., Liechti, F. D., Grandgirard, D., Bigas, J., Seco, J., Tarrago, T., Leib, S. L., & Khrestchatisky, M. (2014) · Progress in Brain Research · doi:10.1016/b978-0-444-63486-3.00014-1 · Cited by 52
Chauhan, P., Kakkar, A. K., Singh, H., & Gautam, C. S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1838276 · Cited by 12
Metadata
- Authors
- Brundula, V., Rewcastle, N. B., Metz, L. M., Bernard, C. C., & Yong, V. W.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-06
- Volume
- 125
- Issue
- 6
- Pages
- 1297-1308
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2286903127
- Cited by
- 426
- References
- 42
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.